SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB)
- 20 January 2009
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 33 (5) , 479-482
- https://doi.org/10.1016/j.ijantimicag.2008.10.028
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Advances in the Treatment of TuberculosisClinical Pharmacology & Therapeutics, 2007
- Phenothiazines as Anti-Multi-Drug Resistant Tubercular AgentsInfectious Disorders - Drug Targets, 2007
- Vascular activity of two silicon compounds, ALIS 409 and ALIS 421, novel multidrug-resistance reverting agents in cancer cellsCancer Chemotherapy and Pharmacology, 2007
- In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosisInternational Journal of Antimicrobial Agents, 2007
- WHO's new Stop TB StrategyThe Lancet, 2006
- Direct Application of the INNO-LiPA Rif.TB Line-Probe Assay for Rapid Identification of Mycobacterium tuberculosis Complex Strains and Detection of Rifampin Resistance in 360 Smear-Positive Respiratory Specimens from an Area of High Incidence of Multidrug-Resistant TuberculosisJournal of Clinical Microbiology, 2005
- Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Multicenter Laboratory Validation of Susceptibility Testing of Mycobacterium tuberculosis against Classical Second-Line and Newer Antimicrobial Drugs by Using the Radiometric BACTEC 460 Technique and the Proportion Method with Solid MediaJournal of Clinical Microbiology, 1999